安罗替尼联合PD-1单抗二线治疗晚期非小细胞肺癌的效果及不良事件分析OA

Objective:To investigate the effect and adverse events of Anlotinib combined with programmed death receptor 1(PD-1)monoclonal antibody second-line therapy for patients with advanced non-small cell lung cancer(NSCLC).Method:From January 2020 to May 2025,80 patients with advanced NSCLC who received second-line treatment in Zunyi First People's Hospital were selected and divided into two groups by random number table method,the control group(n=40)received PD-1 monoclonal antibody second-line treatment,the observation group(n=40)received Anlotinib combined with PD-1 monoclonal antibody second-line treatment.The treatment cycle was 3 weeks,both groups received 4 cycles of treatment.The disease control effects one month after treatment and incidence of adverse events between two groups were compared,serum carcinoembryonic antigen(CEA),cytokeratin 19 fragment(CYFRA21-1),and vascular endothelial growth factor(VEGF)levels were detected before and after treatment,the quality of life questionnaire-core 30(QLQ-C30)score was evaluated.Result:The disease control rate(DCR)in the observation group was 82.50%,significantly higher than 62.50%in the control group(P<0.05).The levels of CEA,CYFRA21-1,and VEGF in the observation group after treatment were significantly lower than those in the control group,while the QLQ-C30 scores were significantly better than those in the control group(P<0.05).There was no statistically significant difference in the incidence of adverse events between the two groups(P>0.05).Conclusion:Anlotinib combined with PD-1 monoclonal antibody second-line treatment can improve DCR and enhance quality of life in patients with advanced NSCLC,its adverse events are tolerable.